close

Agreements

Date: 0000-00-00

Type of information: Construction of new premises

Compound: vaccine manufacturing site in Val de Reuil

Company:

Therapeutic area: Infectious diseases

Type agreement: construction of new premises

Action mechanism:

Disease: influenza

Details:

  • • On October 12, 2017, Sanofi announced that the group is investing €170 million to expand a vaccine manufacturing site in Val de Reuil, France. The expansion further strengthens Sanofi’s position as one of the world’s leading seasonal flu vaccine providers.
  • The new facility will allow Sanofi Pasteur, the Vaccines global business unit of Sanofi, to expand supply of VaxigripTetra® to up to 70 countries in six continents. The new quadrivalent influenza vaccine contains two A strains and two B strains of influenza virus, as per World Health Organization recommendation.
  • The new Val de Reuil facility will be the only site of its kind in France and Sanofi Pasteur remains the sole influenza vaccine producer in the country. Sanofi plans to complete the expansion by 2021, subject to relevant health authority approvals, and will begin producing vaccines in this new facility in 2022.
  • The Val de Reuil manufacturing was founded in 1973 in the Normandy Region of France, 100 km northwest of Paris. It covers all the steps involved in manufacturing a vaccine: antigen production, formulation, stages of pharmaceutical preparation (filling, inspection and packaging) and quality control. The site also includes Sanofi Pasteur's global vaccine distribution center and ships around 900 million vaccine doses worldwide each year.
 

Financial terms:

Latest news:

Is general: Yes